See the DrugPatentWatch profile for Ranolazine
What “ranolazine hetero patent” usually means
People often search this phrase when they want to know whether Hetero (the Indian pharma company, Hetero Drugs) has a patent position tied to ranolazine, such as a process patent, a formulation patent, or patents covering a product they sell. The word “hetero” can also appear in patent documents because Hetero is an applicant/assignee, a licensee, or an involved company in litigation or generic entry.
To answer precisely, we need the exact patent reference (publication number) or the exact product context (country/market and whether it’s about the drug substance, a finished tablet, or manufacturing).
How to look up the right ranolazine patents for Hetero
If you’re trying to verify a “Hetero ranolazine” patent, the most reliable approach is to search patent databases using combinations of:
- “ranolazine” + “Hetero”
- “ranolazine” + “Hetero Labs” / “Hetero Drugs”
- “ranolazine” + “WO” (international filings) or the target country (e.g., “US”, “EP”, “IN”)
In the results, check fields like “applicant/assignee” and “inventor” and whether the patent is about:
- a specific crystalline form/polymorph,
- a particular formulation (tablet composition, extended-release matrix),
- a coating or release profile,
- a manufacturing/process step for the active ingredient or intermediates.
Is there a “hetero patent” that blocks ranolazine generics?
Whether a Hetero patent can block ranolazine competition depends on:
- the jurisdiction (US vs EU vs India, etc.),
- the type of patent (composition vs method vs use),
- the remaining term (expiration vs still in force),
- whether the patent is being enforced against a specific competitor’s product (and where litigation is happening).
A common reason this question comes up is that generic entrants often rely on freedom-to-operate analyses to avoid infringing active patents tied to ranolazine’s formulation or manufacturing. But “Hetero has a patent” does not automatically mean it blocks all ranolazine generics; it only blocks specific claims in specific countries.
Which ranolazine patents matter most for generic approvals
For ranolazine, the practical patent focus usually falls on:
- composition-of-matter claims (drug substance/form),
- formulation claims (especially for extended-release),
- process claims (how the active ingredient is made or purified),
- method-of-treatment claims (less common for brand-blocking unless still active and tightly defined).
If you tell me the country and the market product name (e.g., extended-release vs immediate-release) I can narrow what claim types are typically most relevant.
What to provide so I can identify the exact Hetero ranolazine patent
Reply with any one of the following and I can map it to the right patent and explain what it covers:
- a patent number (e.g., US/EP/WO + number),
- a patent publication link,
- the Hetero company name used in the document (e.g., “Hetero Labs Limited”),
- the country you care about (US, EU, India, etc.),
- whether you mean patents for the drug substance or the finished ranolazine tablet.
Potential pitfalls in searches
- “Hetero” may appear in search results for reasons unrelated to ranolazine (assignment history, citations, or unrelated filings).
- Multiple patents may exist for ranolazine; some are composition/form, others are process, and others are just references.
- Patents can expire, be limited, or be invalidated in litigation; a currently indexed record may not reflect enforceability.
Sources
No sources were provided in the prompt, so I can’t cite a specific “Hetero ranolazine” patent yet.
If you paste the patent publication number or the link you found, I’ll identify what it covers, its likely status/term, and how it relates to generic or branded ranolazine in the relevant jurisdiction.